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abstRact
IntroductIon: The pharmacokinetics of excipients in neo-
nates differs from that of older children. In a recent pan- 
 European survey, two thirds of neonates received at least 
one potentially harmful excipient, such as ethanol and ben-
zoates. The content of sweeteners varied by route of ad-
ministration (more common by enteral than parenteral 
route) and regional differences were revealed. The survey 
did not identify if the content of excipients was more pro-
nounced in medications prescribed for specific medical dis-
eases, e.g. more common in cardiovascular conditions than 
lung diseases. Furthermore, the quantitative amount of e.g. 
ethanol in the multi-medicated neonate has not been inves-
tigated. The aim of the present study is to quantify the total 
amount of excipients administered to poly-medicated neo-
natal and paediatric patients during hospitalisation; and to 
investigate if any particular medical diseases are treated 
with potentially harmful excipients. 
Methods: This is a retrospective cohort study based on 
chart-audit on multi-medicated patients ≤ 5 years of age 
treated at the Rigshospitalet, Denmark. Preparations with 
ethanol, propylene glycol, benzyl alcohol, parabens, acesul-
fame p, aspartame, glycerol, sorbitol and polysorbate-80 will 
be recorded and cumulative amounts will be calculated. 
conclusIon: By quantifying the amount of harmful excipi-
ents to which paediatric patients are exposed, the study will 
contribute to a risk/benefit assessment of the medication 
standards of neonatal and paediatric patients. 
FundIng: The Danish Council for Independent Research, 
grant-id: DFF – 6110-00266. 
trIal regIstratIon: This study was registered at clinicaltri-
als.gov (reg. no. NCT02545712).
Development of paediatric formulations, particularly 
those suitable for neonates and young children, can be 
challenging. There is only limited knowledge available on 
the acceptability of different dosage forms, tastes, and – 
importantly – the safety of formulation excipients in rela-
tion to children’s age and development stage. In general, 
pharmaceutical excipients exhibit many critical functions 
that are necessary to maintain, e.g. the quality and palpa-
bility of the active pharmaceutical ingredient (API) drug, 
without being pharmacologically active themselves [1]. 
Despite their widespread use in both licenced and 
unlicensed medications [2, 3], our knowledge about the 
safety characteristics of these ”inert” excipients remains 
very limited [4]. Some can be classified as “acceptable” or 
“neutral” because their use triggers no safety concerns, 
whereas others may be considered “controversial” as 
their use can be associated with certain risks of adverse 
drug events. Excipients such as benzyl alcohol and poly-
sorbate-80 have previously been associated with in-
creased mortality in neonates [5, 6] and methyl-paraben 
and propyl-paraben have been linked with  
cases of hyperbilirubinemia [7] in the same population, 
whereas artificial sweeteners such as aspartame and ace-
sulfame potassium (previously acesulfame p) may de-
crease insulin sensitivity in neonates [8]. The preser-
vatives ethanol and propylene glycol serve as solvents and 
microbial preservatives and are some of the most com-
monly used solvents in oral liquid mediations [9]. Both 
are known to affect the development of the central nerv-
ous system (CNS) [3, 10, 11] and may thus be character-
ised as harmful. Studies and observations on foetal alco-
hol effects in children give direct evidence of the grave 
deleterious effects of chronic ethanol exposure, for exam-
ple, on neurological and cognitive developmental pro-
cesses [12]. 
Ethanol intake secondary to medication administra-
tion was recently measured in 15 neonates [13]. The 
study measured the blood ethanol levels after administra-
tion of one or a maximum of two eth anol-containing 
preparations. Approximately one third of blood ethanol 
levels were above the recommendations of the European 
Medicines Agency following a single dose of one or two 
ethanol-containing medications. Especially in preterm 
and term neonates, the immature metabolic pathways 
will affect the clearance of both the active pharmaceutical 
ingredient and the excipients. Further, some excipients 
and APIs are metabolised by some of the same enzymatic 
pathways [14], e.g. ethanol and paracetamol. Thus, the 
vulnerable multi-medicated neonatal and young paediat-
ric patient may be at increased risk of accumulating toxic 
levels of the API and/or the excipient of interest (EOI) 
[14]. Despite their “non-pharmacological” activity, excip-
ients may pose a health risk to both the short-term and 
the long-term well-being of the patient if the exposure 
exceeds clin ically relevant levels [9]. The harmful effects 
include ethanol-induced CNS depression [3] and foetal 
alcohol syndrome [12]. Further more, propylene glycol 
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has been associated with eth anol-like-intoxication and 
neurotoxicity [15], whereas both benzyl alcohol and poly-
sorbate-80 in medication have resulted in death among 
low-birth-weight infants [5, 6]. Though several studies 
have described the potentially harmful effects of ethanol 
in neonates and young children, a narrative study from 
2014 was unable to describe an international consensus 
on ethanol-tolerance levels in neonates or young children 
[15]. Moreover,  the American Association of Paediatrics 
(AAP), the Food and Drug Administration (FDA) and 
the European Medical Agency (EMA) currently propose 
different limits for the level of tolerable ethanol in medi-
cation to neonates and young children [16-18]. Limits 
vary from 25 mg/dl (AAP), 0.5% v/v (FDA) to 1  
mg/dl (EMA) – all of these are limits for a single dose of 
medication. Only the EMA proposes a daily limit of eth-
anol ingestion of 6 mg/kg/day, thus acknowledging the 
potential of accumulative excipient exposure through two 
or more medications. 
In Denmark, no studies have yet described the ex-
tent of excipient exposure or the quantity of excipient ex-
posure in multi-medicated neonatal and paediatric pa-
tients. 
The purpose of this study is to quantify the amount 
of potentially harmful EOIs – presented in table 1 – ad-
ministered to the multi-medicated neonatal and young 
paediatric patient. Further, it will identify the most vul-
nerable group of patients, thus possibly allowing the  
clinician to make appropriate decisions for a safer medi-
cation.
mEthOds
The study will adopt a retrospective, observational de-
sign to describe the extent of excipient exposure in neo-
natal and young paediatric patients from Rigshospitalet, 
Copenhagen, Denmark. 
Ethics approval and consent
The protocol was approved by The Board for Patient 
Safety, Danish Health and Medicines Authority (ID: 
3-3013-1343/1/). The Board has waived the requirement 
for patient consent.
Furthermore, the study was approved by The 
Danish Data Committee (ID: BFH-2015-072 and I-Suite 
number: 04167). 
study selection
The study only involves patients who were treated at 
Rigshospitalet during the time period from 1 February 
2006 to 14 February 2016. 
For further inclusion and exclusion criteria, see 
table 2. 
data collection
Data will be collected in the course of a journal audit in-
cluding > 1,000 patients meeting the inclusion criteria 
and not complying with any of the exclusion criteria. Pa-
tients are identified through admission to a neonatal or 
paediatric unit, but may also be included if treated in an 
adult department on the day of inclusion. The day of in-
clusion is set to the day the neonate or child is adminis-
tered the highest number of unique preparations. 
The following information will be collected: 
– Danish civil registration (CPR) number
– Gestational age 
– Postmenstrual age (if different from gestational age)
– Weight (and whether actual or adjusted medical 
weight is stated, e.g. due to overhydration)
– Pregnancy and birth history 
– Treated at neonatal, paediatric or adult department
– Diagnosis (by the International Classification of 
Diseases, 10th edition (ICD-10))
tablE 1
Excipients of interest.
Preservatives
Ethanol
Propylene glycol
Benzyl alcohol
Methyl-hydroxybenzoatea, methyl-paraben
Propanyl-hydroxybenzoatea, propyl-paraben
Artificial sweeteners
Acesulfame potassiumb
Aspartame
Glycerol
Sorbitol
Polysorbate-80
a) The sodium-associated parabens included. 
b) Previously acesulfame p.
tablE 2
Inclusion and exclusion criteria for the study population.
Inclusion criteria
Neonatal patientsa: receiving ≥ 2 preparations a day
Paediatric patientsb: receiving ≥ 3 preparations a day
Hospitalised at least once:
At either department 5021, 5023, 5024, 4144, 5054, 5061 or  
5062 at Rigshospitalet
During the period 1 February 2006-14 February 2016
Exclusion criteria
> 5 yrs old
No weight information available in patient chart
a) ≤ 27 days old (gestational age). 
b) 28 days-5 yrs old (gestational age).
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– Daily medication:
 – Indication
 – Preparation
 – Prescription (off-label/on-label/extemporaneous)
 – Amount
 – Dose
 – Interval
 – Formulation
 – Route of administration.
The patients will be grouped according to the Interna-
tional Conference on Harmonization’s (ICH E11) guide-
lines on ”Clinical Investigation of Medicinal Products in 
the Paediatric Population”:
– 0-27 days (term and pre-term)
– 28 days-23 months
– 2-11 years (please note that patients older than five 
years are excluded, see exclusion criteria).
Excipient identification process
After the data collection, the excipients in each drug will 
be identified through leaflets, monographies via Medicin-
Info BFH or by direct contact to the pharmaceutical 
companies and manufacturers. Depending on origin, the 
process of excipient quantification differs (see Figure 1). 
The concentration of each EOI will be noted. 
Each drug administered will be grouped according 
to excipient contained, type of formulation and 
Anatomical Therapeutic Chemical (ATC) level 1.xxx
For all patients, accumulative daily amounts of the 
EOIs will be calculated based on the collected data 
 (patient weight, drug dose and drug interval) and the in-
formation obtained during the process of excipient iden-
tification and subsequent quantification. The concentra-
tions of ethanol and propylene glycol (the latter being 
one third as intoxicating as ethanol) will be combined to 
calculate the blood-alcohol-content (g/dl).
statistical analysis
By parametric statistical analysis, the study will identify 
the frequency and mean of each excipient. All excipient 
exposures will be compared parametrically with clinic ally 
relevant data to establish if the amount is clinically signif-
icant. The number of patients with an exposure rate 
above clinically significant baselines will be noted.
We will describe the pattern of excipient exposure 
in preparations administered at neonatal, paediatric and 
FigURE 1
Yes
No
No No
Yes
YesNo
Yes
MARKETED PREPARATIONS licensed in Denmark?
Is the manufacturer/distributor known?
Search item-number to
identify manufacturer/
distributor
Does the distributor have 
the SmPC in an internal 
database?
Is the list of ingredients available 
from the manufacturer?
Does the list include any of the
EOIs or potential sources
of hidden excioients?Restricted
database
Restricted
database
Restricted
database
Yes No
No
NoManufacturer
found
Yes
EXTEMPORANEOUS PREPARATIONSa
Has the list of exipients previously been reviewed
by the Medical Information’s Central?
Distributor
found
Search public databases
for SmPC
Does the SmPC list any of the EOIs or 
potential sources of hidden excipients?
No further
research needed
No further
research neededContact the manfacturer
Has SmPC previously 
been reguested by the
Medical Information’s 
cental?
Are the excipients
quantiﬁed?
Public
database
Yes
Yes No
No
Found
Not found
Restricted
database
Restricted
database
Illustration of the process 
of excipient identification 
and quantification.
EOI = excipient of inter-
est; SmPC = summary of 
product characteristics.
a) Includes both prepar-
ations originating from 
community pharmacies 
(Skanderborg and 
Glostrup) and prepara-
tions originating local 
hospital pharmacies.
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adult departments. p-values < 0.05 are considered signifi-
cant.
Outcome measurements
The primary outcome is the identification of the average 
amount of each excipient (listed in Table 1) administered 
secondary to medication.  
Secondary outcomes include:
– Identifying the most frequently used of the included 
excipients 
– Calculating an average of each excipient to which 
each main group and subgroup was exposed
– Description of the pattern of excipient exposure for 
patients admitted to a neonatal unit compared with a 
paediatric unit and with an adult unit
– Contribution to a risk/benefit assessment of the  
current medication standards of the paediatric popu-
lation.
Funding statements
The study has received grants from the Bispebjerg and 
Frederiksberg Hospitals’ Research Foundation and the 
Danish Council for Independent Research (Grant-ID: 
DFF – 6110-00266). Neither these nor any future funders 
will have any influence on the data collection, analysis, 
interpretation and decision to publish.
discUssiOn
Preservatives and artificial sweeteners used as excipi-
ents may cause harm to the exposed neonatal and pae-
diatric patients. Three decades ago, a detailed review 
was performed of the medical records of all babies 
weighing less than 1,250 g at birth admitted to a neo-
natal intensive care unit. The study aimed to assess the 
true impact of benzyl alcohol toxicity after the use of so-
lutions containing benzyl alcohol to flush intravascular 
catheters was discontinued. The study found a signifi-
cant decrease in both the mortality rate (from 80.7% to 
45.7%) and in the incidence of grade III/IV intraventricu-
lar haemorrhage (from 46% to 19%) among infants 
weighing less than 1,000 g at birth who did not receive 
the preservative compared with those who did [5]. To-
day, the EMA states that any medication containing ben-
zyl alcohol ”must not be given to premature babies and 
neonates” [19, 20]. A similar approach could be taken to 
other controversial excipients such as ethanol, but be-
fore proposing such regulations it is important to evalu-
ate the harmful potential of the total  ethanol exposure 
in the vulnerable neonates and young children. 
In the present study, medication administered to 
patients up to five years of age will be examined to as-
sess the excipient exposure during the most vulnerable 
maturing period of the central nervous system. 
In 2015, we examined the monographs of 85 oral 
solutions (ATC level 7) prescribed during 2014 at one or 
several children’s units at Rigshospitalet, Copenhagen, 
tablE 3
Pilot examination of monographs of 85 oral solutionsa.
Excipient contained in preparations Frequency of excipient
Ethanol Methadon SAD 13
Methadon, non-SAD
Fenemal
Trileptal
Sulfametoxazol
Mycostatin, 100,000 IE/ml
Mycostatin, 100,000 IE/mlb
Digoxin
Zofran
Dexofan
Glycifer
Potassium chloride
Sandimmun Neoral
Propylene glycol Paracetamol 12
Bonyl
Fenemal
Tegretol
Trileptal
Valcyte
Aerius
Digoxin
Ritrovil
Chloralhydrat
Ursofalk
Sandimmun Neoral
Benzyl alcohol Dalacin   1
Acesulfame potassium Levetiracetam   5
Keppra
Zinnat
Fucidin
Phenergan
Aspartame Zinnat   5
Azithromycin Stada
Xaluprine
Zofran
Cellcept, Orifarm
Glycerol Paracetamol 13
Bonyl
Levetiracetam
Keppra
Zovir, 40 mg/ml
Zovir, 80 mg/ml
Sulfametoxazol
Esimeprazol
Retrovir
Mycostatin, 100.000 IE/ml
Mycostatin, 100.000 IE/mlb
Noxafil
Chloralhydrate
a) The examination of the monographs did not take into account oral solutions containing benzoates, 
sorbitol or polysorbate-80; b) Mycostatin 100,000 IE/ml is counted twice due to different parallel im-
porters with different package sizes.
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Denmark (see table 3). The oral solutions were both of 
marketed and extemporaneous origin. Among the oral 
solutions, we found that 34 different drug preparations 
(40%) contained at least one of the excipients included 
herein. Ethanol, propylene glycol and glycerol were 
found with the highest frequency (at 13, 12 and 13 re-
spectively – see Table 3). Only one drug contained benzyl 
alcohol. This preview does not provide information on 
the poly-medicated patient, who is at risk of being ex-
posed to significant amounts of the same excipient from 
mul tiple drugs, but it emphasises the need for an examin-
ation of patient-level excipient exposure. To this day, 
there is an ongoing discussion of excipients in neonatal 
and paediatric marketed and extemporaneous drugs. 
Patients included in this study originate from a highly 
specialised hospital and thus may both represent children 
requiring specialist treatment and the typical neonatal or 
young paediatric patient. Thus, results will reflect the use 
of both specialist preparations and the most commonly 
used preparations. The prevalence of each excipient may 
differ from the one that would have been observed if the 
study had been conducted at a gen eral hospital. Several 
studies have stated that  
younger patients are exposed to harmful and/or  
potentially harmful excipients such as parabens, aspart-
ame, etc. [2, 3, 5, 8]. None of these studies aspire to quan-
tifying the exact amount of excipients administered to the 
poly-medicated patient through drugs. 
In order to perform a proper risk/benefit assess-
ment of the current medication standard, it is necessary 
to compare the daily quantity of excipients in the most 
vulnerable patient to clinically established safety levels 
for the same age group. The SEEN project is relevant 
both nationally and internationally as it will reveal the 
current status of excipients (frequency and amount) in 
medicines administered to neonates and young children. 
Perspectives
The SEEN project will contribute to a discussion of the 
current medication standards and the use of off-licensed 
and extemporaneous drugs in neonatal and paediatric 
hospital units in Denmark and internationally. It is our 
hope that this will facilitate clinical research by covering 
aspects related to e.g., the safety, efficacy, dosing and for-
mulations currently most used in this vulnerable group. 
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